Directive EEC - PILs PATIENT ACCESS SCHEMES Christine Gilmour co-chair of NHS Scotland Patient Access Scheme Assessment Group.

Slides:



Advertisements
Similar presentations
Guidance Note on Joint Programming
Advertisements

Workstream 4 Primary Care Surge Capacity & Business Continuity Issues of focus Where we are now Key challenges.
Senior Manager – Research Finance & Programmes
© Safeguarding public health Expert Group on Innovation in the Regulation of Healthcare products Adaptive Licencing workshop at the Wellcome Trust October.
1 Attributing the costs of health & social care Research & Development – Understanding AcoRD Trudi Simmons Senior Manager – Research Finance & Programmes.
New Trials If you are seeking a collaboration with the UCL CCTU we require you to apply: At least 3 months before the application deadline By using the.
BROMI Variations – An Industry Perspective
Scottish Medicines Consortium (SMC) User Group Forum Priorities
Highly Specialised Technologies Evaluations
BOPA Patient Access Scheme – Clinical Pharmacist View David Thomson, Lead Pharmacist, YCN Chair, BOPA.
Japan Audit & Supervisory Board Members Association (JASBA) Explanatory Memorandum on the Audit & Supervisory Board Members (The companies with Audit &
West Midlands (North) Comprehensive Local Research Network Streamlining Research Management and Governance Arrangements Single Assessment Service & Research.
IAEA International Atomic Energy Agency Responsibility for Radiation Safety Day 8 – Lecture 4.
FOUNDATION TRUST STATUS. What is a Foundation Trust? It is an NHS organisation, first established in April 2004 Foundation Trusts operate according to.
Mitigation and Extenuating Circumstances
Patient Interest Seminar 21 st May Dr. Andrew Power Vice Chair New Drugs Sub group.
SMC Evaluation Programme. Overview Context Evaluation Programme –Stakeholders –SMC advice Conclusions.
Collaborative Clinical Medicines Procurement (CCMP) “Getting Value for Money” Colette Whigham Category Manager – Pharmacy NHS National Procurement, Scotland.
Role of Pharmacoeconomics in a Developing country context Gavin Steel for Anban Pillay Cluster Manager: Health Economics National Department of Health.
CADTH Therapeutic Reviews
Pharmacy & National Procurement Christine Gilmour Chief Pharmacist NHS Lanarkshire.
Hepatitis C Action Plan: Phase II Programme Management Approach.
Promoting Excellence in Family Medicine Enabling Patients to Access Electronic Health Records Guidance for Health Professionals.
Frequently Asked Questions (FAQ) prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9.
NMC revalidation Frances Cannon SPO NIPEC –
ZHRC/HTI Financial Management Training
Emergency Unit Management: a guide to better practice Basil Bonner Head: Emergency Unit Milnerton Medi-Clinic.
Diabetes Programme Progress Report Dr Charles Gostling, Joint Diabetes Clinical Director October 2013.
Quality Education for a Healthier Scotland Celebrating 10 years of Practice Education Facilitation in Scotland Dr Colette Ferguson Director of Nursing,
You need to consider whether a Patient Group Direction (PGD) would be appropriate for an area of practice that involves the supply or administration of.
The Tayside Experience The Long Road To Implementation Peter Rice, Consultant Psychiatrist, NHS Tayside Alcohol Problems Service.
Draft Code of Practice – General Consultation / Implementation Sue Woodgate.
Practitioner & Counter Services NSS Involving People Event 5 th March 2014 Canderside.
A quick guide to CQC registration May Key concepts This quick overview of key concepts will help you decide what registration means for you:  What.
1 INTERREG IIIB “ATLANTIC AREA” Main points of community regulation 438/2001 financial management and control systems EUROPEAN COMMISSION SPAIN.
 Minor Ailment Service.  Policy To establish community pharmacies as the first port of call for the NHS treatment of common clinical.
Retha Britz Copyright 2013 All rights reserved for this presentation 1 Establishment and functioning of a REC Retha Britz.
1 Collaborative Provision and External Examining Nicola Clarke Centre for Academic Standards and Quality Enhancement (CASQE)
RO Training Day Organisational Structure for the Delivery of Enhanced Appraisal in Scotland Ian G Finlay Scottish Government Health Directorates.
MINISTRY OF HEALTH Update on the implementation of SOI Milestones Hanoi, March 2010.
SMC Horizon Scanning Anne Lee, Scottish Medicines Consortium Julia Earnshaw, GlaxoSmithKline.
Stakeholders In Clinical Research The Pharma Company Professor Phil Warner.
Your Ambulance Service Foundation Trust Consultation.
Audit Advisory Committee Public health transition update 22 January 2013.
Programme for Health Service Improvement Clinical Services Planning Group Moving forward CARDIFF AND VALE NHS TRUST YMDDIRIEDOLAETH GIG CAERDYDD A’R FRO.
ESIF Technical Compliance Requirements May 2015 WORKSHOP Helen Joicey.
Scottish Medicines Consortium SMC RESPONSE TO EVALUATION Angela Timoney Vice Chair SMC 23 rd September 2008.
Building Clinical Infrastructure and Expert Support Michael Steinberg, MD, FACR ULAAC Disparity Project Centinela/Freeman Health System.
Name Position Organisation Date. What is data integration? Dataset A Dataset B Integrated dataset Education data + EMPLOYMENT data = understanding education.
Current Challenges and Future Developments in HTA in the UK Frances Macdonald, 23 rd September 2008 (A personal, Industry View)
What will this presentation do? Explain what Single Assessment Process is and where it comes from Explain how Single Assessment will improve older peoples.
SMC Evaluation Project The View From Industry Martin Coombes Government Affairs Manager, AstraZeneca ABPI Representative SMC Evaluation Reference Group.
Contracts of Employment. This is a legal document which sets out the details of a person’s employment. This is a legal document which sets out the details.
International Atomic Energy Agency Roles and responsibilities for development of disposal facilities Phil Metcalf Workshop on Strategy and Methodologies.
We are a group of national health and care organisations working together to provide a joined up and consistent approach to information governance. We.
Assessment Toolkit Referral Allocation Meeting (RAM) Team Meetings RAM Accepted into service ALL REFERRALS Administration Standard Referral form (on intranet)
PHE Local Intelligence Contribution David Meechan, Director for Knowledge & Intelligence (East Midlands), Public Health England.
Risk Sharing Schemes Dr Rafiq Hasan Director of Market Access
SMC and the role of Public Involvement Action Duchenne Scottish Mini Conference 4 December 2015 Lindsay Lockhart Public Involvement Officer.
NATIONAL INITIATIVES: BEST PRACTICE AND LESSONS LEARNED FROM SCOTTISH EXPERIENCE Alan MacDonald Vice Chairman Scottish Medicines Consortium Hard Choices.
New medicines, new challenges: the SMC approach
Session 6: Data Flow, Data Management, and Data Quality.
Health and Social Care Integration Update Name Role October 2015.
Effective Board Governance & role of the Audit Committee Presentation by Cluster Audit Committee – July / August 2012.
AUDIT STAFF TRAINING WORKSHOP 13 TH – 14 TH NOVEMBER 2014, HILTON HOTEL NAIROBI AUDIT PLANNING 1.
NHS Milton Keynes CCG Constitution This document is not a legal document and is not to be used as a replacement for the full version of the NHS Milton.
Project Management PTM721S
Guidance notes for Project Manager
Kaisa Immonen EPF Director of Policy
Presentation transcript:

Directive EEC - PILs PATIENT ACCESS SCHEMES Christine Gilmour co-chair of NHS Scotland Patient Access Scheme Assessment Group

Directive EEC - PILs 1.How are schemes reviewed at National level? 2.What is the impact of multiple schemes on the NHS? 3.How are access schemes costed?

Directive EEC - PILs What is a PAS? A pricing scheme proposed by a pharmaceutical company to improve the cost effectiveness of a medicine, thereby facilitating patient access.

Directive EEC - PILs Origins of PAS 2009 Pharmaceutical Price Regulation Scheme between DOH and ABPI Pricing is a reserved matter – but it is for the devolved administrations to meet their policy and operational requirements.

Directive EEC - PILs Types of PAS Financial schemes = the NHS receives a rebate or free supply based on usage irrespective of response. Performance schemes = the rebate or supply of patient stock is based on patient response to treatment.

Directive EEC - PILs PPRS Principles PAS = the exception Priority to schemes that deliver greatest benefit to patients e.g. unmet need Cumulative burden must remain manageable

Directive EEC - PILs NHS Scotland Response Transitional PASAG July 09 – March 10 To develop and pilot procedures to –receive, –assess –communicate output to relevant parties. Business Case to Scottish Govt to resource a PAS national service.

Directive EEC - PILs Remit of PASAG To deliver a national service for Scotland which will: Assess PAS on a national basis Communicate output to identified stakeholders. Produce guidance notes for NHS Scotland. Monitor uptake and benefits of PAS in Scotland.

Directive EEC - PILs PASAG Membership Co-chaired by Director of Pharmacy and Director of Finance Membership ( n = 18) includes : –pharmacy –finance –clinicians –operational and senior NHS management –public health –procurement –information specialists –pharmaceutical industry Observers: SGHD, SMC, NHS QIS, CLO

Directive EEC - PILs Key Functions of PASAG Industry Guidance & Application Pack –PAS Industry checklist; PAS template; PAS submission Form; PAS Approval letter Standard T’s & C’s for PAS in Scotland (legal operational framework) Implementation Pack for NHS Boards –PAS submission form (standard template) –PAS approval form (standard template) –Guidance notes : operational flow chart and monitoring template process (specific to each medicine) Maintain a register of PAS submissions

Directive EEC - PILs Types of PAS Simple PAS = fits with normal processes e.g. a discount from list price with no patient tracking. Complex PAS = anything else. –Rebate based on patient response –Rebate based number of courses of treatment –Rebate based on patient weight etc –Free of charge stock for initiation of therapy –Free treatment after a preset period

Directive EEC - PILs CATEGORISATION of SCHEMES PAS Performance scheme COMPLEX (response dependent) Finance scheme SIMPLE (straight discount) COMPLEX (all other rebates)

Directive EEC - PILs Assessment Criteria Patient Confidentiality – meets Data protection and information governance requirements Legally compliant – meets legal framework in Scotland Clinically robust – clinical care and patient numbers fit Operational – is it workable in NHS Scotland health systems Financially viable – running costs in context of proposed rebate

Directive EEC - PILs PASAG Meetings National meetings held monthly to enable the output to synchronize with the monthly SMC meetings. 12 meetings per annum equating to an estimated maximum capacity of 36 PAS assessed per annum.

Directive EEC - PILs Secretariat – liaison with company Pre-submission = generic advice only Post-submission = clarification of PAS, resolution of show stoppers. Post decision = nominated members of PASAG

Directive EEC - PILs Process Flow Submission via SMC secretariat Generic PAS questions to SMC clinical experts PAS questions to NHS operational staff Cost to operate the scheme identified PAS Assessment Proforma completed by Secretariat and submitted to PASAG for decision. SMC informed of decision SMC consider drug with/without PAS as appropriate

Directive EEC - PILs Costing a PAS All activities costed, e.g. time to develop data base, time to write SOPs, time to record scripts, time to process claims etc. Costs based on all territorial Boards participating Costs done twice based projected patient numbers Top of pay scale plus on costs – although duties may be delegated

Directive EEC - PILs PASAG ‘yes’ & SMC ‘yes’ Pack to support implementation of the PAS by NHS Boards is prepared. Pack includes a PAS Monitoring Template to facilitate development of the PAS Monitoring Database by NHS Boards Pack issued to NHS Boards via SMC. PAS referred to in the SMC Detailed Advice Document

Directive EEC - PILs PASAG ‘no’ and SMC ‘no’ Medicine only via individual patient treatment request No national PAS implementation pack The decision on the PAS does not stand alone - it is part of the SMC consideration SMC feedback negative SMC decision PASAG offer same opportunity to feedback on the PAS. Resubmission is via SMC

Directive EEC - PILs PASAG ‘yes’ & SMC ‘no’ SMC feedback negative SMC decision Medicine only available via individual patient treatment request No national PAS implementation pack Boards arrange local rebate Resubmission is via SMC

Directive EEC - PILs PAS ‘no’ & SMC ‘yes’ Drug may be prescribed without PAS – e.g. Lenalidomide

Directive EEC - PILs Individual Board signs up to the PAS Forms sent to company, copied to Finance, details recorded on the PAS Monitoring Database in accordance with SOP. Registration, claim forms etc completed in accordance with SOP Board develops SOP and Monitoring Database Rebate etc recorded on the PAS Monitoring Database. Verification Record is provided to PASAG or the company on reasonable request, as appropriate, excluding any patient identifiable information. Eligible patients registered & assigned PAS patient number

Directive EEC - PILs Unique PAS Patient Number PAS Number/Location code/Patient Number Allocated to an approved scheme by PASAG after SMC has reviewed the PAS medicine. Included in guidance notes sent to NHS Boards. Relates to the NHS Board of treatment. Taken from the Location Code Directory maintained by ISD. Assigned by Boards to eligible patients receiving medicine via the PAS.

Directive EEC - PILs Verification Record Link to Patient Record (must not be disclosed) Unique PAS Patient Number Dose Date treatment started Date treatment finished Date of claim Date credit received Board of residence where not Board of treatment

Directive EEC - PILs Learning to Date Feasible is not the same as acceptable 12 PAS assessed 8 PAS accepted (PAS yes is not an SMC yes) 4 PAS not accepted Most PAS = finance based Most finance schemes = rebate on initial treatment, followed by % discount on list price

Directive EEC - PILs Learning contd. Assessment takes 8 weeks Not the exception Unmet need FOI Stakeholder Engagement – NHS Boards / Industry / HTA organisations

Directive EEC - PILs Issues Range of schemes - standardisation required Lack of fit with NHS processes –not clinical trials Patient tracking Individual patient stock Cumulative burden Tertiary Centres & repatriation